Predicting Weight Loss After Pharmacological or Surgical Treatment in Patients With Obesity

May 11, 2026 updated by: Université Catholique de Louvain

Research of Predictive Factors of Weight Loss After Pharmacological or Surgical Treatment in Patients Suffering From Obesity

As with other nutritional strategies, the clinical response to bariatric surgery can be highly variable, with weight regain being a frequent occurrence. Recent evidence on anti-obesity medication indicate similar inter-individual variability in clinical response. Among multiples factors, co-occurrence of eating disorders such as binge eating disorder has been implicated in insufficient clinical response. Improving our ability to predict how patients will respond to obesity treatment is necessary in order to tailor the care pathways we offer. The mechanisms involved in disturbances of eating behaviour before and after surgery remain largely unknown. This study aims to identify the predictive factors of weight loss after pharmacological or surgical treatment, as well as the cognitive and biological mechanisms that mediate this effect.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Observational

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
100

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Contact Backup

Study Locations

  • Belgium
    • Brussels Capital
      • Brussels, Brussels Capital, Belgium, 1200
        • Recruiting
        • Cliniques universitaires Saint-Luc
        • Contact:
        • Principal Investigator:
          • Yannick Deswysen, Doctor
        • Sub-Investigator:
          • Audrey Loumaye, Professor

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Participants initiating an anti-obesity medication or candidates for bariatric surgery once its indication has been validated by a multidisciplinary committee, following medical, nutritional and psychological evaluations.

Description

Inclusion criteria:

  • Age between 18 and 65 years
  • Obesity, with bariatric surgery indicated after a multidisciplinary evaluation in case of surgical treatment.
  • Good physical and mental health, enabling informed consent.
  • French speaker

Exclusion criteria:

  • Legal protection
  • Pregnancy or breastfeeding
  • History of bariatric surgery (except gastric banding, provided it was removed more than five years ago).
  • Acute or progressive chronic disease
  • Alcohol consumption of more than 20 g/day
  • Inflammatory bowel disease;
  • Digestive autonomic diabetic neuropathy.
  • Consumption of dietary supplements (stanols, probiotics, prebiotics or omega-3).
  • Following a vegan or gluten-free diet or being lactose intolerant.
  • Fibre consumption >30 g/day
  • Recent change in antidiabetic medication within the past 3 months.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Correlation between weight loss after treatment and clinical, neuropsychological and biological parameters.
Time Frame: Throughout the entire study, aproximately during 5 years

The percentage of excessive weight loss after treatment will be correlated with

  • Clinical parameters (Binge Eating Scale and modified Yale Food Addiction Scale 2.0)
  • Neuropsychological parameter (Barratt Impulsivness Scale and Trail Making Test)
  • Biological parameters
Throughout the entire study, aproximately during 5 years

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Binge Eating Disorder.
Time Frame: Throughout the entire study, aproximately during 5 years
Evaluation of eating disorders using the Binge Eating Scale (BES).
Throughout the entire study, aproximately during 5 years
Food Addiction.
Time Frame: Throughout the entire study, aproximately during 5 years
Evaluation of food addiction will be performed using modified Yale Food Addiction Scale 2.0.
Throughout the entire study, aproximately during 5 years
Eating attitudes
Time Frame: Throughout the entire study, aproximately during 5 years
Eating patterns and habits will be screened using the Eating Attitude Test 26
Throughout the entire study, aproximately during 5 years
Cognitive flexibility.
Time Frame: Throughout the entire study, aproximately during 5 years
Neuropsychological evaluation of cognitive flexibility will be performed with the Trail Making Test
Throughout the entire study, aproximately during 5 years
Impulsivity.
Time Frame: Throughout the entire study, aproximately during 5 years
Impulsivity will be assessed using the Barrat Impulsiveness Scale (BIS)
Throughout the entire study, aproximately during 5 years
Self-reported quality of life.
Time Frame: Throughout the entire study, aproximately during 5 years
Self-reported quality of life will be assessed using the QOLOD (Quality of Life, Obesity and Dietetics)
Throughout the entire study, aproximately during 5 years
Obesity.
Time Frame: Throughout the entire study, aproximately during 5 years
Weight will be measured at each timepoint
Throughout the entire study, aproximately during 5 years
Physical activity.
Time Frame: Throughout the entire study, aproximately during 5 years
Weekly physical activity will be reported with the Godin Leisure Time Exercise Questionnaire (GLTEQ)
Throughout the entire study, aproximately during 5 years
Food intake.
Time Frame: Throughout the entire study, aproximately during 5 years
Eating habits will be recorded with a Food Frequency Questionnaire (FFQ)
Throughout the entire study, aproximately during 5 years
Blood samples
Time Frame: Throughout the entire study, aproximately during 5 years
Blood samples will be collected and processed for metabolomic analyses.
Throughout the entire study, aproximately during 5 years
Fecal sample
Time Frame: Throughout the entire study, aproximately during 5 years
Feces samples will be collected and processed to evaluation gut-microbiota composition
Throughout the entire study, aproximately during 5 years

Other Outcome Measures

Other Outcome Measures

For clinical trials, a planned measurement described in the protocol that is used to determine the effect of an intervention/treatment on participants. For observational studies, a measurement or observation that is used to describe patterns of diseases or traits, or associations with exposures, risk factors, or treatment. Types of outcome measures include primary outcome measure and secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Sociodemographic data
Time Frame: Once at inclusion
Number of children and marital status will be recorded
Once at inclusion
Medical history
Time Frame: Once at inclusion
Information concerning medical comorbidities will be collected from the patient medical record.
Once at inclusion
Childhood Trauma.
Time Frame: Once at inclusion
Assessment of adverse life events and trauma will used the Childhood Trauma Questionnaire - short form.
Once at inclusion

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Université Catholique de Louvain

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Study Director: Amandine Everard, Professor, Université Catholique de Louvain

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
May 5, 2026

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
June 1, 2032

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
January 1, 2036

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
January 13, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
February 6, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
February 11, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
May 14, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
May 11, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
May 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • TCAPrediBaria

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings